Key Highlights

● United Therapeutics reported first-half 2026 total Revenue of about $1,564.8 million and Net Income of roughly $607.9 million, and agreed in July 2026 to acquire Thymmune Therapeutics for $140.0 million upfront plus up to $160.0 million in milestones.

● Sotera Health raised full-year 2026 guidance on 6 August 2026 to net revenues of $1.236 billion to $1.254 billion after first-half revenue grew roughly 9.6% to about $601.4 million.

● Larimar Therapeutics submitted the first module of a rolling Biologics License Application for nomlabofusp in Friedreich's ataxia on 29 June 2026, with all nine one-year study participants achieving skin frataxin levels above the target threshold.

● Kamada reported record first-half 2026 revenue of about $100.2 million, up roughly 13%, and reaffirmed full-year guidance of $200 million to $205 million in revenue.

Five very different Nasdaq-listed names, a tiny eye-disease developer, a profitable pulmonary-hypertension giant, a sterilization-services operator, a rare-disease pioneer awaiting an FDA decision, and a specialty plasma company, map the full risk spectrum of healthcare as autumn trading gets underway.

A Snapshot of Where Healthcare Sits This September

Healthcare rarely moves as one block, and this cluster shows why. Together, Kiora Pharmaceuticals (NASDAQ: KPRX), United Therapeutics (NASDAQ: UTHR), Sotera Health (NASDAQ: SHC), Larimar Therapeutics (NASDAQ: LRMR) and Kamada (NASDAQ: KMDA) span clinical-stage speculation, durable commercial cash flow, essential infrastructure and near-term regulatory catalysts. Each is a Nasdaq constituent, so each feeds the Nasdaq Composite's healthcare weighting in its own way, some through momentum, others through steady fundamentals.

What these five companies actually reported through mid-2026, and what investors might reasonably watch next, is the focus below.

The Sector Backdrop Heading Into Autumn 2026

The healthcare narrative in 2026 has been shaped by two forces pulling in opposite directions. On one side, the Cost of Capital still matters intensely for pre-revenue biotech, where cash runway and dilution risk govern share performance more than any single data point. On the other, established commercial biopharma and health-technology infrastructure have offered investors the ballast of real revenue and, in several cases, share buybacks.

That split runs straight through these five tickers. United Therapeutics and Sotera Health sit on the cash-generating end; Kiora and Larimar occupy the catalyst-and-runway end; Kamada bridges the two as a profitable but still-growing specialty player. Regulatory calendars, plasma economics, sterilization Demand and rare-disease approval pathways all feature below, a reminder that biotech and health tech is really a dozen distinct businesses wearing one label. With rate expectations still fluid, the market's tolerance for long-dated clinical stories could shift quickly, making balance-sheet strength a recurring theme this quarter.

Kiora Pharmaceuticals (NASDAQ:KPRX): A Micro-Cap Ophthalmology Bet With Runway to Spare

Kiora Pharmaceuticals is a clinical-stage ophthalmology developer, and its appeal, and its risk, is concentrated in two mid-stage programs.

In its second-quarter 2026 update, reported August 2026, Kiora said it held roughly $16.8 million in combined cash and short-term investments as of June 30, 2026, and projected that resources would fund operations into late 2028. The company reported a net loss of about $2.1 million for the quarter. Its lead asset, KIO-301 for retinitis pigmentosa, is being studied in the Phase 2 ABACUS-2 trial, which advanced into a higher-dose cohort; Kiora guided to last-patient-first-visit in Q1 2027 and topline data in Q3 2027. A second candidate, KIO-104 for macular edema, is in the KLARITY Phase 2 study, with initial data expected in late 2026. KIO-301 is partnered with Thea Open Innovation, which holds commercialization rights across major markets and reimburses development costs.

The Thea Partnership is the structural point that separates Kiora from many cash-hungry peers, since reimbursed development stretches the runway and validates the science. The late-2026 KLARITY readout is the nearer catalyst, but for a company this size, any single trial outcome could move the stock sharply in either direction.

United Therapeutics (NASDAQ:UTHR): Profitable Scale, Plus an Organ-Manufacturing Moonshot

United Therapeutics is the commercial anchor of this group, a profitable biopharma built on pulmonary-hypertension franchises, now investing in the far frontier of manufactured organs.

For the first half of 2026, United Therapeutics reported total revenue of about $1,564.8 million, down modestly from $1,593.0 million a year earlier, with net income of roughly $607.9 million. Second-quarter revenue was about $783.3 million. Product-level H1 disclosures included Tyvaso DPI at roughly $656.9 million, nebulized Tyvaso at about $253.2 million, Orenitram near $261.3 million, Remodulin around $252.9 million and Unituxin at about $118.8 million. The company disclosed an accelerated share repurchase in H1 2026 and a July 2026 agreement to acquire Thymmune Therapeutics for $140.0 million upfront plus up to $160.0 million in milestones. Separately, United Therapeutics has publicly advanced its UKidney xenotransplantation program, announcing the first transplant in its EXPAND clinical trial in November 2025.

The revenue dip year over year is worth watching, but the Balance Sheet and buyback signal confidence. The organ-manufacturing effort, spanning xenotransplantation and the Thymmune tie-up, is a long-horizon option layered on top of a paying business. Clinical progress in EXPAND and integration of new Assets are multi-year stories, not quarterly ones.

Sotera Health (NASDAQ:SHC): The Sterilization Backbone Behind Medical Devices

Sotera Health is less a drug story than critical health-technology infrastructure, sterilization and lab-testing services that medical-device and pharmaceutical customers cannot easily do without.

For H1 2026, Sotera reported net revenues of about $601.4 million, up roughly 9.6% year over year, with net income of approximately $80.2 million. Second-quarter revenue was about $321.4 million. By segment for the half, Sterigenics contributed roughly $397.7 million, Nelson Labs about $112.6 million and Nordion around $91.2 million. On August 6, 2026, management raised full-year 2026 guidance, now targeting net revenues of $1.236 billion to $1.254 billion, adjusted EBITDA of $634 million to $643 million, and adjusted EPS of $0.95 to $1.01. The company also disclosed net long-term Debt of roughly $2.13 billion.

The recurring, contracted nature of sterilization demand is the attraction here, as it tends to track underlying device volumes rather than drug-approval lotteries. The offset is leverage: a debt load above $2 billion means interest costs and refinancing conditions matter. The raised outlook suggests management sees steady demand, but debt servicing keeps rate sensitivity firmly in the picture.

Larimar Therapeutics (NASDAQ:LRMR): A Friedreich's Ataxia Filing Reaches the FDA

Larimar Therapeutics is the purest regulatory-catalyst story of the five, built around a single rare-disease candidate now in front of the FDA.

Larimar's lead program, nomlabofusp, targets Friedreich's ataxia, a progressive genetic disorder. The company has said the candidate holds FDA Breakthrough Therapy designation. On June 29, 2026, Larimar announced it had submitted the first module of a rolling Biologics License Application seeking accelerated approval, with remaining modules expected in the second half of 2026. It reported that, at one year, all nine participants in an open-label study achieved skin frataxin levels above 8.2 pg/microgram, with mean skin frataxin rising from 3.7 pg/microgram at baseline to 12.1 pg/microgram, and cited a 2.6-point difference in mFARS scores versus a natural-history reference group. Larimar guided to first Phase 3 dosing in Q3 2026 and, if approved, a potential launch around mid-2027.

A rolling BLA plus Breakthrough designation compresses the timeline meaningfully, and frataxin as a surrogate endpoint is the crux of the accelerated-approval case. Completion of the filing and any FDA feedback are the defining events ahead; rare-disease approvals carry real uncertainty, and outcomes are binary for a company of this profile.

Kamada (NASDAQ:KMDA): Specialty Plasma Therapeutics With Record Results

Kamada rounds out the group as a profitable, growing specialty plasma-derived therapeutics company, a rare combination of biotech and steady cash generation.

For H1 2026, Kamada reported record total revenue of about $100.2 million, up roughly 13% year over year, with net income near $13.4 million and adjusted EBITDA of about $25.7 million. Second-quarter revenue was about $54.9 million, up around 23%. The company reaffirmed full-year 2026 guidance of $200 million to $205 million in revenue and $50 million to $53 million in adjusted EBITDA. Its portfolio includes six FDA-approved specialty products, among them KEDRAB, CYTOGAM, GLASSIA, VARIZIG, WINRHO SDF and HEPAGAM B. Kamada also operates three FDA-approved plasma collection centers in Texas and disclosed a roughly $50 million three-year sales agreement, with initial commercial sales expected in Q4 2026.

Kamada's differentiation is that it is already profitable, so growth compounds rather than merely burning capital. Owning plasma collection vertically integrates a costly input. Reaffirmed guidance implies management confidence, but plasma-derived businesses depend on collection volumes and Supply chains that can tighten.

What Investors Should Watch

Near-term catalysts differ by name. For Kiora, the late-2026 KLARITY readout and 2027 ABACUS-2 data are the markers. For Larimar, completion of the rolling BLA in the second half of 2026 and any regulatory feedback dominate. For Kamada, the Q4 2026 start of its new supply agreement and progress toward guidance are the checkpoints.

For United Therapeutics and Sotera Health, the questions are more about durability, whether United's franchises stabilize and its organ programs advance, and whether Sotera's raised outlook holds against its debt load. Across all five, the macro overlay of interest rates and biotech risk appetite remains the common thread.

A Sterilizer, a Plasma Grower and Three Regulatory Clocks

Kiora and Larimar offer high-variance, catalyst-driven exposure where cash runway and single readouts rule. Kamada and Sotera provide profitable operations with distinct risks, plasma supply and financial leverage, respectively. United Therapeutics blends dependable Cash Flow with a speculative organ-manufacturing bet.

How each performs into 2027 will hinge on execution against the specific milestones above, not on any shared sector tailwind.